A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)

Downloadstatistik des Dokuments (Auswertung nach COUNTER):

Lange, Angar; Prenzler, Anne; Frank, Martin; Golpon, H.; Welte, T. et al.: A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC). In: BMC Pulmonary Medicine 14(2014), Nr. 1, 192. DOI: http://dx.doi.org/10.1186/1471-2466-14-192

Version im Repositorium

Zum Zitieren der Version im Repositorium verwenden Sie bitte diesen DOI: https://doi.org/10.15488/550

Zeitraum, für den die Download-Zahlen angezeigt werden:

Jahr: 
Monat: 

Summe der Downloads: 162




Kleine Vorschau
Zusammenfassung: 
Background: Non-small cell lung cancer (NSCLC) imposes a substantial burden on patients, health care systems and society due to increasing incidence and poor survival rates. In recent years, advances in the treatment of metastatic NSCLC have resulted from the introduction of targeted therapies. However, the application of these new agents increases treatment costs considerably. The objective of this article is to review the economic evidence of targeted therapies in metastatic NSCLC. Methods: A systematic literature review was conducted to identify cost-effectiveness (CE) as well as cost-utility studies. Medline, Embase, SciSearch, Cochrane, and 9 other databases were searched from 2000 through April 2013 (including update) for full-text publications. The quality of the studies was assessed via the validated Quality of Health Economic Studies (QHES) instrument. Results: Nineteen studies (including update) involving the MoAb bevacizumab and the Tyrosine-kinase inhibitors erlotinib and gefitinib met all inclusion criteria. The majority of studies analyzed the CE of first-line maintenance and second-line treatment with erlotinib. Five studies dealt with bevacizumab in first-line regimes. Gefitinib and pharmacogenomic profiling were each covered by only two studies. Furthermore, the available evidence was of only fair quality. Conclusion: First-line maintenance treatment with erlotinib compared to Best Supportive Care (BSC) can be considered cost-effective. In comparison to docetaxel, erlotinib is likely to be cost-effective in subsequent treatment regimens as well. The insights for bevacizumab are miscellaneous. There are findings that gefitinib is cost-effective in first- and second-line treatment, however, based on only two studies. The role of pharmacogenomic testing needs to be evaluated. Therefore, future research should improve the available evidence and consider pharmacogenomic profiling as specified by the European Medicines Agency. Upcoming agents like crizotinib and afatinib need to be analyzed as well.
Lizenzbestimmungen: CC BY 2.0
Publikationstyp: article
Publikationsstatus: publishedVersion
Erstveröffentlichung: 2014
Die Publikation erscheint in Sammlung(en):Wirtschaftswissenschaftliche Fakultät

Verteilung der Downloads über den gewählten Zeitraum:

Herkunft der Downloads nach Ländern:

Pos. Land Downloads
Anzahl Proz.
1 image of flag of Germany Germany 105 64,81%
2 image of flag of United States United States 11 6,79%
3 image of flag of United Kingdom United Kingdom 11 6,79%
4 image of flag of Russian Federation Russian Federation 9 5,56%
5 image of flag of Hong Kong Hong Kong 5 3,09%
6 image of flag of India India 3 1,85%
7 image of flag of Israel Israel 3 1,85%
8 image of flag of No geo information available No geo information available 2 1,23%
9 image of flag of Morocco Morocco 2 1,23%
10 image of flag of Austria Austria 2 1,23%
    andere 9 5,56%

Weitere Download-Zahlen und Ranglisten:


Hinweis

Zur Erhebung der Downloadstatistiken kommen entsprechend dem „COUNTER Code of Practice for e-Resources“ international anerkannte Regeln und Normen zur Anwendung. COUNTER ist eine internationale Non-Profit-Organisation, in der Bibliotheksverbände, Datenbankanbieter und Verlage gemeinsam an Standards zur Erhebung, Speicherung und Verarbeitung von Nutzungsdaten elektronischer Ressourcen arbeiten, welche so Objektivität und Vergleichbarkeit gewährleisten sollen. Es werden hierbei ausschließlich Zugriffe auf die entsprechenden Volltexte ausgewertet, keine Aufrufe der Website an sich.

Suche im Repositorium


Durchblättern